Truffle Report

24/02/2022

What makes pe**te unique among psychedelics?

Lophos Pharma is a **te focused psychedelics company co-founded by wife and husband duo Claire and Evan Stawnyczy to explore mescaline’s therapeutic potential.

President and Chief Executive Officer Claire says that, “We have examples of carbon-dated pe**te going back 5000 years, which show humans have been using this as a medicine for millennia. It’s a plant that is currently under-researched but has the longest documented use of any natural psychedelic.”

Read the full interview here: http://ow.ly/Igs650I3vQC

17/02/2022

The push for medical is on. Truffle Report looks at top corporate and scientific developments involving the spirit molecule from MindMed, Algernon Pharmaceuticals Inc., Entheon Biomedical, Small Pharma and more.

Full article here: http://ow.ly/fKNE50HXPbj

16/02/2022

A Hawaii legislative committee has approved a bill that proposes the establishment of a working group to study the therapeutic benefits of by a vote of 5-0.

Read the full story here: http://ow.ly/n5Am50HWKEk

15/02/2022

For the new psychedelic industry, current psilocybin growing and extraction techniques have their challenges. In recent years, researchers from Miami University and Danmarks Tekniske Universitet - DTU have begun exploring biologically-derived alternatives.

Read the full article here: http://ow.ly/YbOF50HVOg0

14/02/2022

A group of 10 Maryland State Senators is co-sponsoring a new bill proposing a state fund to provide military veterans suffering from PTSD free access to a range of psychedelic therapies.

Full story here: http://ow.ly/20VU50HUPWN

14/02/2022

Our newest installment of Truffle Talks is here. In this latest episode, we sat down with Dr. Bia Labate of the Chacruna Institute to talk about some of the great work being done by this pioneering nonprofit.

Watch the full video here: http://ow.ly/nHEK50HUupf

Truffle Talks interview with Dr. Bia Labate of the Chacruna Institute for Psychedelic Plant Medicines. Feb. 10, 2022.

11/02/2022

With new ETF inclusions, patent approvals, and supply agreements, it's been another big week for the business of .

We've got the latest news from atai Life Sciences, CybinInc, HAVN Life, and PharmAla Biotech.

Full roundup here: http://ow.ly/5U7050HT1Yw

Top psychedelic business news for the week for Feb 7-11, including stocks, regulatory approvals and sales agreements.

10/02/2022

Clinical trials are considered the gold standard for drug development, but they're slow by nature, cumbersome, and in the case of , often redundant in terms of placebo controls.

Truffle Report looks at the use of real-world evidence in psychedelic research as an alternative.

Full article here: http://ow.ly/9Op250HS9fl

09/02/2022

Social anxiety disorder (SAD) involves extreme fear or anxiety about being ridiculed or scrutinized in social situations and lasts at least six months. This fear can cause significant distress and negatively impact an individual’s quality of life. The average age of onset in SAD patients is between 10 to 13 years, and SAD is rarely diagnosed after the age of 25.

Truffle Report looks at ketamine for the treatment of social anxiety disorder.

Full article here: http://ow.ly/RBFE50HQX4n

09/02/2022

From The New York Times. We had the pleasure of interviewing Dr. George Greer on this subject back in 2020, and got some fascinating anecdotes on the progress in this area prior to the scheduling of M**A.

For some couples on the brink of divorce, taking the illegal psychedelic drug was a last resort — but it ended up being the only thing that worked.

09/02/2022

04/02/2022

According to TPC - Therapeutic Psilocybin for Canadians, healthcare professionals are being abruptly denied access to mushrooms for training purposes via Section 56 exemptions, following a decision by Canadian health authorities.

Full story here: http://ow.ly/Ggj950HN4f7

04/02/2022

It's been another big week in business news, with a new ETF launching, and regulatory and financial updates from Mydecine Innovations Group, Entheon Biomedical, and Small Pharma.

Read our full roundup here: http://ow.ly/lbOW50HMRsy

Top psychedelic business news stories for Jan 31-Feb 4 including stocks, regulatory approvals, and financial reports.

03/02/2022

Michigan voters may be able to have their say on the legal status of drugs this coming November, thanks to a statewide ballot initiative filed by activists including Decriminalize Nature Michigan and Students for Sensible Drug Policy.

If approved, the ballot measure would introduce legislation that would allow for the “supervision, guidance, therapeutic, harm reduction, spiritual, counseling, and other related supportive services with or without remuneration” for adults engaging in the intentional and consenting use of natural plants and mushrooms.

Full story here: http://ow.ly/1C1q50HM0q3

03/02/2022

It's new Truffle Talks time. This week's installment is a great chat with C.J. Spotswood, aka The EntheoNurse about Maine's services bill, psychedelic drug interactions, and the evolving conversation around harm reduction.

C.J. Spotswood, MSN, APRN, PMHNP, is a board certified psychiatric-mental health nurse practitioner with his practice in primary care in central Maine.

Watch the full episode here: http://ow.ly/brOx50HLJ0z

02/02/2022

Lawmakers in the State of Maine have heard evidence in favour of and against a bill seeking to establish a regulatory framework for accessing products in the state.

The bill, “An Act to Enact the Maine Psilocybin Services Act” (LD1582), went before the Joint Standing Committee on Health and Human Services on Tuesday.

LD1582 would appoint the Maine Psilocybin Advisory Board, similar to Oregon’s approach for creating a framework to access psilocybin therapy. The board’s duties would include making recommendations to Maine’s Department of Health and Human Services related to “the available medical, psychological and scientific studies, research and other information on the safety and efficacy of psilocybin in treating behavioral health conditions, including but not limited to substance use disorder, depression, anxiety disorders, and end-of-life psychological distress.”

Read the full story here: http://ow.ly/NnB550HKNUl

02/02/2022

Already scarce and time-consuming to cultivate, the life cycle of the **te cactus in Mexico and the traditions of indigenous people are being threatened by mining operations.

Full article here: http://ow.ly/ze7P50HKCag

01/02/2022

From the ancient Aztecs to modern microdosers, stacking with sweets, herbs, and other admixtures has a rich and colourful history.

Similar to the broader practice of microdosing, researchers speculate that the growing popularity of stacking has stemmed from “the proliferation of positive anecdotal reports over the past decade, rather than from a strong empirical basis.”

Read the full article here: http://ow.ly/eI8050HJzVP

31/01/2022

Earlier this month, Health Canada granted healthcare professionals trained and supervised by ATMA Journey Centers permission to consume psilocybin in a clinical trial to demonstrate safety.

Full story here: http://ow.ly/4IxK50HIlun

ATMA Journey Centers is launching a clinical trial for the safety of synthetic psilocybin among trained healthcare professionals in mid-2022

28/01/2022

Is it Friday already? Truffle Report has your weekly roundup of business news, with stories from MindMed Numinus, Filament Health, the Multidisciplinary Association for Psychedelic Studies (MAPS) and Mindcure.

Read the full article here: http://ow.ly/LTng50HGPCF

28/01/2022

Truffle Report was at yesterday's Microdose event, checking out the Public vs. Private Markets panel hosted by Richard Skaife of The Conscious Fund and featuring Klee Irwin of Irwin Naturals and Quantum Gravity Research, Bill O'Hara of LACG Capital Inc., and Matt King of Valhalla Ventures.

You can find our full coverage here: http://ow.ly/C4QK50HGMIy

markets

27/01/2022

A bill introduced by Dawn M. Adams - Delegate, Virginia HD68 proposing to decriminalize the possession of certain naturally-occurring drugs for clinical use in Virginia has been delayed until 2023.

Read the full story here: http://ow.ly/FbLl50HFYtT

27/01/2022

New Truffle Talks is live! On this week's episode, we spoke to Chris Koddermann of the International Therapeutic Psilocybin Rescheduling Initiative (ITPRI) about what it would take to reschedule on the world stage.

Watch the full video here: http://ow.ly/yfeI50HFP7C

26/01/2022

Research on in the State of Oklahoma may soon be streamlined with the filing of two new bills last week by Representatives Logan Phillips and Daniel Pae.

Read the full story here: http://ow.ly/PJe250HET96

25/01/2022

More than 10 million people worldwide live with Parkinson’s Disease. Truffle Report has put together a review of prospective treatments and trials involving from leading institutions like Yale University and the TrPR_Program at UCSF.

Full article here: http://ow.ly/xqz450HCITg

24/01/2022

Can you experience withdrawal?

Chemical dependence isn't usually an issue with psychedelics, but it's important to examine your relationship with any substance, particularly one that is fast becoming a mental health fix.

Full article here: https://www.truffle.report/can-you-experience-psilocybin-withdrawal/

22/01/2022

Introduced by Representative Peter Merideth, a new bill in Missouri proposes to significantly decrease penalties for possession of , , and other controlled substances.

Full story here: http://ow.ly/mN9y50HAAvY

21/01/2022

Our weekly business update is here, with top news stories from Numinus, Filament Health, Psygen Labs Inc. and Optimi Health.

Read the full article here: http://ow.ly/vyQY50HAbro

Top psychedelic business news stories from January 17-21, including clinical trials, financial reports, regulatory developments, and patents.

21/01/2022

To balance out the high-pressure world of professional sports, some athletes look to to improve their mental health and performance. Truffle Report reached out to former Philadelphia Flyer Riley Cote to learn more.

Read the full article here: http://ow.ly/Noyw50HA4Uf

20/01/2022

In a letter addressed to the Drug Enforcement Administration - DEA a bipartisan group of Representatives including Earl Blumenauer, Congressman Don Bacon, Congresswoman Rashida Tlaib, Congressman Andy Biggs, Congresswoman Sheila Jackson Lee, Rep. Dean Phillips, and Rep. Madeleine Dean, asked the agency to allow terminal patients access to therapeutic treatments.

“Research demonstrates that psilocybin provides immediate, substantial, and sustained relief from debilitating anxiety and depression in individuals with terminal illnesses,” the letter says. “We strongly believe that our constituents suffering such illnesses should have access to this investigational drug should they decide to pursue such a course of treatment,” the lawmakers added.

Full story here: http://ow.ly/tQqQ50HzhGn

19/01/2022

This week's Truffle Talks is live! In our new episode, we sit down with artist, tech entrepreneur, and enthusiast Raad Seraj to discuss a better future for investing in the sector.

Full video here: http://ow.ly/4CBj50HysZ4

New Approaches to Psychedelic Investing with Raad Seraj: Truffle Talks Episode 11 - Truffle Report

19/01/2022

A new bill introduced in Utah by Representative Brady Brammer may pave the way for the state to allow as psychotherapy drugs to treat specific mental health conditions.

Full story here: http://ow.ly/AsmZ50HyeBX

18/01/2022

Lawmakers Dawn M. Adams - Delegate, Virginia HD68 and Senator Ghazala Hashmi are attempting to downgrade penalties for possession of substances in the State of Virginia with new bills introduced last week.

Full story here: http://ow.ly/Nbfc50Hx2h7

17/01/2022

A coalition of scientists and advocates from the International Therapeutic Psilocybin Rescheduling initiative are working to reschedule at a global level.

Truffle Report reached out to ITPRI co-founder Chris Kodderman for details.

Read the full story here: http://ow.ly/OM9j50HwcLH

14/01/2022

Pharmacists are the most accessible healthcare professionals to the general public. In the event of FDA approval of psychedelic medicine for anxiety, depression, PTSD and other psychiatric indications, pharmacists will play a pivotal role in the implementation of psychedelics in healthcare.

In our first attempt to cover the role of pharmacists in the evolving field of , a few of our readers expressed an understandable skepticism as to the willingness of these professionals to take the risk of commenting on these issues in their day-to-day practice. Truffle Report reached out to the Psychedelic Pharmacists Association with some of these concerns.

Read the full article here: http://ow.ly/JCVX50HuWEJ

14/01/2022

Truffle Report's weekly business news roundup is live. We have regulatory and Special Access updates from atai Life Sciences, Field Trip Health, Mydecine Innovations Group, and Wesana Health.

You can read the full article here: http://ow.ly/N4oz50HuPus

13/01/2022

Special Guest Post: While Health Canada's recent Special Access Program amendments surrounding are a victory for patients, doctors, and industry, guest writer Michael Kydd says they are also an important test.

Read the full Op-Ed here: http://ow.ly/44vL50HtXB4

13/01/2022

For our People & Perspectives section. Does contribute to wellness and calm in a yoga practice? We asked a dedicated amateur yogi cultivating her own .

Read the full article here: http://ow.ly/xGth50HtQi5

12/01/2022

For those of you who like our editor's voice but don't care for his face, all of our Truffle Talks episodes are now available in podcast form on Spotify.

Give them a listen here: http://ow.ly/O49S50Ht99m

Listen to Truffle Talks on Spotify. Truffle Report is dedicated to bringing you the best of the psychedelic space. Truffle Talks is our new interview series where we sit down with the movers and shakers defining psychedelic business, policy reform, science, and culture. Find us online: https://www.t...

12/01/2022

Episode 10 of Truffle Talks is live! In this installment, we sit down with Dr. Pamela Kryskow and Cory Firth of the Canadian Psychedelic Association to discuss important milestones in policy, medicine, and culture.

Watch the full interview here: http://ow.ly/8tAS50HsWq2